Remnant cholesterol

Remnant cholesterol is the cholesterol content of triglyceride-rich lipoprotein (TRL) remnants — primarily VLDL and IDL in the fasting state, and chylomicron remnants postprandially. It is calculated as total cholesterol minus LDL-C minus HDL-C, avoiding specialised assays, though direct measurement yields higher absolute values. TRL remnants below ~70 nm traverse the arterial endothelium by active transcytosis, accumulate in the intima, and trigger foam-cell formation and endothelial dysfunction; each particle carries up to four times the cholesterol load of an LDL particle. Mendelian randomization in the Copenhagen General Population Study (Varbo et al., 2013 — 73,513 participants) estimated a causal odds ratio of 2.8 (95% CI 1.9–4.2) per 1 mmol/L genetic increase in nonfasting remnant cholesterol for ischemic heart disease, independent of HDL-C. Genetic instruments targeting TRIB1, GCKR, and APOA5 reinforce this causal inference and explain much of the residual cardiovascular risk in statin-treated patients with well-controlled LDL-C. Optimal fasting remnant cholesterol is generally placed below 0.5 mmol/L (~19 mg/dL); levels at or above 1.5 mmol/L (~58 mg/dL) are associated with ~1.9- to 2.3-fold higher myocardial infarction hazard in prospective Copenhagen cohort data. Because TRL metabolism worsens with insulin resistance and visceral adiposity — conditions linked to accelerated biological aging — elevated remnant cholesterol may partly mediate excess cardiovascular mortality in metabolic aging phenotypes.